Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 3:15 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 109 matching trials from the live ClinicalTrials.gov search.
Conditions
Food Allergy
Interventions
linvoseltamab, dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Tampa, Florida • Atlanta, Georgia • Boston, Massachusetts + 2 more
Conditions
Peanut Allergy
Interventions
AR101 powder provided in capsules, Placebo powder provided in capsules
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 26 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Little Rock, Arkansas • San Diego, California • Boston, Massachusetts + 5 more
Conditions
Food Allergy
Interventions
Not listed
Lead sponsor
Food Allergy Support Team
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Sarasota, Florida
Conditions
Food Hypersensitivity
Interventions
Open label peanut OIT
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
4 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed Not applicable Interventional Results available

Predicting Peanut Anaphylaxis and Reducing Epinephrine

NCT05696236
Conditions
Anaphylaxis Food
Interventions
Transepidermal water loss (TEWL) monitor and stopping rules, Monitor (TEWL) without stopping rules
Device
Lead sponsor
University of Michigan
Other
Eligibility
6 Months to 5 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Peanut Allergies
Interventions
MY006 Low Dose, MY006 Mid Dose, MY006 High Dose, MY006 Selected Dose, Placebo (Vehicle)
Drug
Lead sponsor
Mabylon AG
Industry
Eligibility
12 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
9
States / cities
Little Rock, Arkansas • Aurora, Colorado • Colorado Springs, Colorado + 6 more
Completed Phase 3 Interventional Results available

PALISADE Follow-on Study (ARC004)

NCT02993107
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
47
States / cities
Tucson, Arizona • Little Rock, Arkansas • Mission Viejo, California + 39 more
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 250µg
Drug
Lead sponsor
DBV Technologies
Industry
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
17
States / cities
Little Rock, Arkansas • San Diego, California • Stanford, California + 13 more
Conditions
Allergy, Peanut
Interventions
DBV712, Placebo
Drug · Other
Lead sponsor
DBV Technologies
Industry
Eligibility
4 Years to 7 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
50
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more
Completed Phase 1Phase 2 Interventional Results available

Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy

NCT05138757
Conditions
Peanut Allergy
Interventions
Prebiotic, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
4 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Chicago, Illinois • Hyde Park, Illinois
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 250 mcg
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
7 Years to 56 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
San Diego, California • Stanford, California • Chicago, Illinois + 6 more
Conditions
Peanut Allergy
Interventions
Fecal Microbiota Capsule
Biological
Lead sponsor
Rima Rachid
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Peanut Allergy
Interventions
Part A Viaskin Peanut 250 mcg, Part A Viaskin Peanut 100 mcg, Part A Placebo, Part B Viaskin Peanut 250 mcg, Part B Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
1 Year to 3 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
27
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more
Conditions
Allergy, Peanut Allergy
Interventions
DBV712 250 mcg, Placebo
Combination Product
Lead sponsor
DBV Technologies
Industry
Eligibility
1 Year to 3 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
56
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more
Completed Phase 2 Interventional Results available

Oral Immunotherapy (OIT) for Peanut Allergy

NCT00815035
Conditions
Peanut Hypersensitivity
Interventions
Peanut OIT, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 6 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Hypersensitivity, Food Allergy, Hypersensitivity, Food, Peanut Hypersensitivity, Peanut Allergy
Interventions
Omalizumab, Dupilumab, Placebo for Dupilumab, Placebo for Omalizumab
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 55 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California
Completed Not applicable Interventional

Immunotherapy for Peanut Allergy

NCT00429429
Conditions
Allergy
Interventions
Sublingual immunotherapy
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 35 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Food Hypersensitivity
Interventions
Peanut SLIT, Placebo SLIT
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 11 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Peanut Allergy
Interventions
AR101, Placebo
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 17 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
62
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 50 more
Recruiting No phase listed Observational Accepts healthy volunteers

Blood Samples for the Study of Peanut, Tree Nut and Other Food Allergies

NCT02192866
Conditions
Peanut Allergies, Tree Nut Allergies, Other Food Allergies
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Year to 75 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2030
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Allergy
Interventions
Oral Food Challenge (OFC): Peanut Protein
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Little Rock, Arkansas • Palo Alto, California • Chicago, Illinois + 7 more
Conditions
Peanut Allergy
Interventions
AR101 - Peanut protein capsule
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 26 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
Little Rock, Arkansas • San Diego, California • Boston, Massachusetts + 5 more
Conditions
Food Hypersensitivity
Interventions
Peanut oral immunotherapy
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
9 Months to 36 Months
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Terminated No phase listed Observational Accepts healthy volunteers

Impact of Vaccination on Th2 Immunity in Infancy

NCT02213341
Conditions
Food Hypersensitivity
Interventions
Skin prick allergen test, Blood draw
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Months to 7 Months
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York